Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | ASAH1 | Q13510 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6075708 | 1.00 | OPRM1 (0.40) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| Hydrochloric Acid SCHEMBL6075710 | 1.00 | OPRM1 (0.40) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6075880 | 0.89 | OPRM1 (0.37) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6075872 | 0.89 | OPRM1 (0.37) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6075755 | 0.88 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6595493 | 0.86 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6595488 | 0.86 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| SCHEMBL6595483 | 0.86 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| Hydrochloric Acid SCHEMBL6075388 | 0.86 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 | |
| Hydrochloric Acid SCHEMBL6075394 | 0.86 | P2RX4 (0.44) | OPRM1OPRD1OPRK1CCKBRDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7008613-B2 | Quaternary ammonium compounds | LES LABORATOIRES SERVIER (FR) | 2006-03-07 | — | — | US | disclosed |
| US-20040208822-A1 | New quaternary ammonium compounds | INSERM (FR) | 2004-10-21 | — | — | US | disclosed |
| US-6759406-B1 | 4-HYDROXY-1,1-DIOXO-1,2-BENZOTHIAZIN-3-YL DERIVATIVES; CARTILAGINOUS TISSUE AFFINITY; LOWER DOASAGE; ARTHRITIS, OSTEOARTHRITIS, CHONDROSARCOMAS | LES LABORATOIRES SERVIER (FR) | 2004-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040208822-A1 | New quaternary ammonium compounds | COL2A1, P4HA1, COL1A1 | OPRM1 356/4885OPRD1 461/4885OPRK1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.